Study Design of a Phase III, Randomized, Placebo-Controlled Trial of Nintedanib in Children and Adolescents with Clinically Significant Fibrosing Interstitial Lung Disease (ILD)

被引：0
|
作者：
Young, L. [1 ]
Brown, K. K. [2 ]
Griese, M. [3 ]
Deutsch, G. [4 ]
Warburton, D. [5 ]
DeBoer, E. [6 ]
Cunningham, S. [7 ]
Clement, A. F. [8 ]
Schwerk, N. [9 ]
Flaherty, K. R. [10 ]
Voss, F. [11 ]
Schmid, U. [11 ]
Schlenker-Herceg, R. [12 ]
Verri, D. [13 ]
Stowasser, S. [14 ]
Clerisme-Beaty, E. M. [14 ]
Deterding, R. R. [6 ]
机构：
[1] Childrens Hosp Philadelphia, Div Pulm Med, Philadelphia, PA 19104 USA
[2] Natl Jewish Hlth, Denver, CO USA
[3] Ludwig Maximilians Univ Munchen, Hauner Childrens Hosp, Munich, Germany
[4] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA
[5] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA
[6] Univ Colorado Denver, Sect Pediat Pulm & Sleep Med, Dept Pediat, Aurora, CO USA
[7] Univ Edinburgh, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland
[8] Sorbonne Univ, Trousseau Hosp, AP HP, Pediat Pulm Dept, Paris, France
[9] Hannover Med Sch, Clin Pediat Pulmonol Allergol & Neonatol, Hannover, Germany
[10] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA
[11] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[12] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[13] Boehringer Ingelheim Italia SpA, Milan, Italy
[14] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2020年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1495
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
    Vincent Cottin
    Fernando J. Martinez
    R. Gisli Jenkins
    John A. Belperio
    Hideya Kitamura
    Maria Molina-Molina
    Inga Tschoepe
    Carl Coeck
    Dirk Lievens
    Ulrich Costabel
    Respiratory Research, 23
  • [22] Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
    Cottin, Vincent
    Martinez, Fernando J.
    Jenkins, R. Gisli
    Belperio, John A.
    Kitamura, Hideya
    Molina-Molina, Maria
    Tschoepe, Inga
    Coeck, Carl
    Lievens, Dirk
    Costabel, Ulrich
    RESPIRATORY RESEARCH, 2022, 23 (01)
  • [23] DESIGN OF A PHASE III, RANDOMISED, PLACEBOCONTROLLED TRIAL OF BI 1015550 IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE
    Maher, T.
    Assassi, S.
    Azuma, A.
    Cottin, V.
    Hoffmann-Vold, A. M.
    Kreuter, M.
    Oldham, J.
    Richeldi, L.
    Valenzuela, C.
    Wijsenbeek, M.
    Coeck, C.
    Voss, F.
    Wachtlin, D.
    Martinez, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1014 - 1015
  • [24] A randomized placebo-controlled trial of oral alendronate children and adolescents with osteogenesis imperfecta
    Ward, LM
    Glorieux, FH
    Rauch, F
    Verbruggen, N
    Heyden, N
    Lombardi, A
    BONE, 2005, 36 : S31 - S31
  • [25] Evaluation of efficacy and safety of rituximab in patients with progressive interstitial lung disease (ILD) with inflammatory component (EvER-ILD2): A multicentre double-blind placebo-controlled randomized trial
    Ferreiraa, Marion
    Bejan-Angoulvantc, Theodora
    Marchand-Adama, Sylvain
    Moussetd, Elodie
    Mureau, Elody
    Jouneaue, Stephane
    Nunesf, Hilario
    Montanig, David
    Chenivesseh, Cecile
    Cadraneli, Jacques
    Bonniaudj, Philippe
    Crestanik, Bruno
    Cottinl, Vincent
    Caillem, Agnes
    RESPIRATORY MEDICINE AND RESEARCH, 2025, 87
  • [26] A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents
    Wagner, KD
    Robb, AS
    Findling, RL
    Jin, JQ
    Gutierrez, MM
    Heydorn, WE
    AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (06): : 1079 - 1083
  • [27] A randomized, placebo-controlled trial of antimicrobial treatment for children with clinically diagnosed acute sinusitis
    Garbutt, JM
    Goldstein, M
    Gellman, E
    Shannon, W
    Littenberg, B
    PEDIATRICS, 2001, 107 (04) : 619 - 625
  • [28] A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
    Vollmer, T. L.
    Sorensen, P. S.
    Selmaj, K.
    Zipp, F.
    Havrdova, E.
    Cohen, J. A.
    Sasson, N.
    Gilgun-Sherki, Y.
    Arnold, D. L.
    JOURNAL OF NEUROLOGY, 2014, 261 (04) : 773 - 783
  • [29] A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
    T. L. Vollmer
    P. S. Sorensen
    K. Selmaj
    F. Zipp
    E. Havrdova
    J. A. Cohen
    N. Sasson
    Y. Gilgun-Sherki
    D. L. Arnold
    Journal of Neurology, 2014, 261 : 773 - 783
  • [30] Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial
    Mankikian, Julie
    Caille, Agnes
    Reynaud-Gaubert, Martine
    Agier, Marie-Sara
    Bermudez, Julien
    Bonniaud, Philippe
    Borie, Raphael
    Brillet, Pierre-Yves
    Cadranel, Jacques
    Court-Fortune, Isabelle
    Crestani, Bruno
    Debray, Marie-Pierre
    Gomez, Emmanuel
    Gondouin, Anne
    Hirschi-Santelmo, Sandrine
    Israel-Biet, Dominique
    Jouneau, Stephane
    Juvin, Karine
    Leger, Julie
    Kerjouan, Mallorie
    Marquette, Charles-Hugo
    Naccache, Jean-Marc
    Nunes, Hilario
    Plantier, Laurent
    Prevot, Gregoire
    Quetant, Sebastien
    Traclet, Julie
    Valentin, Victor
    Uzunhan, Yurdagul
    Wemeau-Stervinou, Lidwine
    Bejan-Angoulvant, Theodora
    Cottin, Vincent
    Marchand-Adam, Sylvain
    EUROPEAN RESPIRATORY JOURNAL, 2023, 61 (06)
12345